EMPE DIAGNOSTICS - MAKING RELIABLE INFORMATION IN THE FIRST CLINICAL MEETING POSSIBLE
MULTIPLEX LATERAL FLOW SIMPLICITY
We offer indigienous, customized, and ready-to-use molecular test kits for the identification of drug-resistance or drug-susceptibility. Our multiplex nucleic acid tests provide YES/NO answers in 70 min by developing a visual signal. Though the versatility of our technology allows high-throughput detection, we are currently focusing on tuberculosis and sexually transmitted infections.
STATE OF THE ART DNA TECHNOLOGY
For the first time in the diagnostic industry, EMPE Diagnostics has combined the highly stringent padlock probe-dependent rolling circle amplification technique and sensitive lateral flow biosensors to enable a pragmatic detection of multiple targets.
The precision of single-molecule detection capacity offers reliable detection of different bacteria, virus, fungus, and other microbes, including their wild types and mutants, allowing them to be appropriately detected in a single test. Our patented technology offers proficient detection of nucleic acids (DNA/RNA) on lateral flow platforms providing highly sensitive visual signals.
No need for expensive equipment. Results in 70 minutes.
Tuberculosis (TB), caused by the bacteria Mycobacterium Tuberculosis (MTB), remains a major health problem for 9.6 million people all over the world, causing 1500 deaths per day. The death rates can increase by up to 78% if TB is associated with immunosuppressive conditions like HIV and/or other sexually transmitted infections (STIs). MBT can develop multi/extensive drug resistance (MDR/XDR), which causes complications that can potentially contribute to life-challenging relapse cases. The patients would in these cases take 2-8 pills and injections, every day for up to 2 years.
Globally, TB-treatment costs more than $10 billion/year, but 20-50% of the patients receive incorrect antibiotics due to the complications of current TB diagnostics. Expensive automated instruments, requirement of infrastructure and skilled personnel at resource-limited clinical centers magnify this problem. Many patients end up spending 10-60% of their family annual income for diagnosis and treatment in the TB-affected countries of Asia, Africa, and some countries in Europe and the US. Ineffective diagnosis and intake of unnecessary antibiotics adversely affects the patient's health and increases the spread of antibiotic resistance, which could ultimately lead to enormous societal and economical problems.
TIMELINE - DETECTION OF MULTI/EXTENSIVELY DRUG RESISTANT TB (M/XDR-TB)
There are more than 12 million people worldwide who suffer from TB-infections. At present, the proper detection of resistant TB genotypes is a long process that takes up to 6 months in developing countries. Clinicians are forced to consider microscopy results due to non-availability of the point-of-care confirmatory diagnostics, especially in primary health centers or entry-level sputum microscopy centers. Therefore, doctors start empirical antibiotic therapy after the first diagnosis.
Failure in correct identification leads to the development of M/XDR-TB, where sophisticated molecular tests and treatment costs about $100-$500 per patient. The second stage evaluation for the confirmation of M/XDR-TB takes about 6 months. However, more than 0.5 million patients develop acute XDR-TB and need to go under isolation. The graphic below explains the current timelines of TB diagnosis and treatment.